Search in:

Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 5

Submit an article Journal homepage

617

Views

CrossRef citations to date

Altmetric

Drug Evaluations

Axitinib for renal cell carcinoma

Guru Sonpavde Genitourinary Oncology Program, Texas Oncology PA and US Oncology Research, 501 Medical Center Blvd, Webster, Houston, TX 77598, USA

, MD,

Thomas E Hutson Director, Genitourinary Oncology Program, Texas Oncology PA and US Oncology Research, Houston, Texas, USA Baylor Sammons Cancer Center, 3535 Worth Street, Dallas, TX 75246, USA

, DO PharmD FACP &

Brian I Rini Associate Professor of Medicine Cleveland Clinic Taussig Cancer Institute, Department of Solid Tumor Oncology and Urology, CCF/CWRU Lerner College of Medicine, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA +1 216 444 9567; +1 216 636 1937; [email protected]

, MD

Pages 741-748 | Published online: 30 Apr 2008

Cite this article
https://doi.org/10.1517/13543784.17.5.741

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Cohen HT, McGovern FJ. Medical progress: renal-cell carcinoma. N Engl J Med 2005;353:2477-90
PubMed Web of Science ®Google Scholar
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27
PubMed Web of Science ®Google Scholar
Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 2002;25:511-8
PubMed Web of Science ®Google Scholar
Chen J, Fujii K, Zhang L, et al. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci USA 2001;98:7783-8
PubMed Web of Science ®Google Scholar
Alavi A, Hood JD, Frausto R, et al. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003;301:94-6
PubMed Web of Science ®Google Scholar
Chen J, Fujii K, Zhang L, et al. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci USA 2001;98:7783-8
PubMed Web of Science ®Google Scholar
Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-14
PubMed Web of Science ®Google Scholar
Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2003;2:S169-77
Google Scholar
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
PubMed Web of Science ®Google Scholar
Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295(21):2516-24
PubMed Web of Science ®Google Scholar
Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16-24
PubMed Web of Science ®Google Scholar
Rini BI, George DJ, Michaelson MD, et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma [abstract 4522]. Proc Am Soc Clin Oncol 2006;24:222s
Google Scholar
Escudier B, Eisen T, Stadler WM, et al. Treatment Approaches in Renal cancer Global Evaluation Trial (TARGETs): A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Sorafenib, an Oral Multi-Kinase Inhibitor in Advanced Renal Cell Carcinoma. N Engl J Med 2007;356(2):125-34
PubMed Web of Science ®Google Scholar
Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):5023
Web of Science ®Google Scholar
Szczylik C, Demkow T, Staehler M, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):5025
Web of Science ®Google Scholar
Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11
PubMed Web of Science ®Google Scholar
Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81
PubMed Web of Science ®Google Scholar
Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma (RCC) response to interleukin-2 based therapy. Proc Am Soc Clin Oncol 2003;22:851
PubMed Web of Science ®Google Scholar
Atkins M, McDermott D, Regan M, et al. Carbonic anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy. Proc Am Soc Clin Oncol 2004;22(14S Suppl):4512
Google Scholar
Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179(1):81-6
PubMed Web of Science ®Google Scholar
Sablin MP, Bouaita L, Balleyguier C, et al. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):5038
PubMed Web of Science ®Google Scholar
Dham A, Dudek AZ. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):5106
PubMed Web of Science ®Google Scholar
Wood CG, Escudier B, Lacombe L, et al. A multicenter, randomized, phase 3 trial of a novel autologous therapeutic vaccine (Vitespen) versus observation as adjuvant therapy in patients at high risk of recurrence after nephrectomy for renal cell carcinoma [abstract 633]. Proc AUA Annual Meeting; 2007; Anaheim, CA, USA
Google Scholar
Hutson TE, Davis ID, Machiels JP, et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 2007;25(18S Suppl):5031
Web of Science ®Google Scholar
Wickman G, Hallin M. Further characterization of the potent VEGF/PDGF receptor tyrosine kinase inhibitor, AG013736, in preclinical tumor models for its antiangiogenesis and antitumor activity. Proc Am Assoc Clin Cancer Res 2003;44:A3780
Google Scholar
Axitinib Investigators Brochure, December 2002, Pfizer, Inc.
Google Scholar
Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-21
PubMed Web of Science ®Google Scholar
Wilmes LJ, Pallavicini MG, Fleming LM, et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 2007;25(3):319-27
PubMed Web of Science ®Google Scholar
Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23(24):5474-83
PubMed Web of Science ®Google Scholar
Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005;23(24):5464-73
PubMed Web of Science ®Google Scholar
Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8(11):975-84
PubMed Web of Science ®Google Scholar
Rixe O, Meric, J, Bloch J, et al. Surrogate markers of activity of AG-013736, a multi-target tyrosine kinase receptor inhibitor, in metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol 2005;23(16S):3003
Google Scholar
Rini BI, Wilding GT, Hudes GR, et al. Axitinib in patients with metastatic renal cell cancer refractory to sorafenib. J Clin Oncol 2007;25 (18S):5032
Google Scholar
Rugo HS, Stopeck A, Joy AA, et al. A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):1003
PubMed Web of Science ®Google Scholar
Schiller JH, Larson T, Ou SI, et al. Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):7507
Google Scholar
Cohen EE, Vokes EE, Rosen LS, et al. A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):6008
Google Scholar
Spano J, Chodkiewicz C, Maurel J, et al. A randomized phase II study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer preceded by a phase I component. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):4551
Web of Science ®Google Scholar
Houk BE, Bello CL, Michaelson MD, et al. Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic/pharmacodynamic (PKPD) approach. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):5027
Google Scholar
Bertolini F, Mancuso P, Shaked Y, Kerbel RS. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today 2007;12(19-20):806-12
PubMed Web of Science ®Google Scholar
Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9(1):327-37
PubMed Web of Science ®Google Scholar
Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
PubMed Web of Science ®Google Scholar
Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6(7):2012-21
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Axitinib for renal cell carcinoma

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Axitinib for renal cell carcinoma

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date